Products for Research Use Only

Trastuzumab

CAT: 0804-HY-P9907-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P9907-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer[1][2][3]. (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
CAS Number
180288-69-1
Product Name Alternative
Anti-Human HER2, Humanized Antibody
UNSPSC
12352203
Hazard Statement
H302, H315, H319, H335
Target
ADC Antibody; EGFR; Radionuclide-Drug Conjugates (RDCs)
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Trastuzumab.html
Purity
99.80
Solubility
H2O
Smiles
[Trastuzumab]
Molecular Weight
(145.36 kDa)
Precautions
H302, H315, H319, H335
References & Citations
[1]Sliwkowski MX, et al. Nonclinical studies addressing the mechanism of action of trastuzumab. Semin Oncol. 1999 Aug;26 (4 Suppl 12) :60-70.|[2]Hudis CA, et al. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357 (1) :39-51.|[3]Barok M, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007 Jul;6 (7) :2065-72.
Shipping Conditions
Blue Ice
Storage Conditions
Store at 4°C for 2 years, do not freeze
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Isoform
ErbB2/HER2; RDC Antibody